CAR-T cell therapy for hard-to-treat autoimmune blood diseases
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This early-stage trial tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and BCMA, in people with autoimmune blood diseases like ITP, AIHA, or Evans syndrome that have not responded to standard treatments. It aims to reset the immune system and reduce production of harmful antibodies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have a confirmed autoimmune blood disease (like ITP, AIHA, or Evans syndrome) that has lasted at least 6 months.
- You have tried at least 2–3 standard treatments, and they did not work well or you cannot take them anymore.
- Your organ function (heart, kidneys, liver) must be good enough, as shown by specific lab tests.
- You must not have certain infections (like HIV, hepatitis) or other serious health conditions (like recent heart problems or tumors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
This trial tests a new type of immune cell therapy called CAR-T cells, which target two proteins (CD19 and BCMA) to reduce inflammation in the gut. It is designed for adults with moderate to severe ulcerative colitis or Crohn's disease that has not responded well to other treatments.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
This trial tests whether a patient's own engineered immune cells (called CD19 CAR-T cells) can calm down overactive immune attacks in several autoimmune diseases like lupus, scleroderma, and myositis. It's for people whose disease isn't controlled by standard treatments.
This trial tests a personalized cell therapy (CAR-T) that targets a protein called CD19 on immune cells. It's for people with certain autoimmune diseases like lupus or scleroderma that are still active despite standard treatments. The goal is to see if this therapy can help control the disease when other options haven't worked.
This trial tests a new type of cell therapy (CAR-T cells designed to target CD19 and BCMA) for children and teenagers with severe autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this one-time infusion can help control the disease and reduce the need for long-term steroids and other drugs.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.